How much funding has OrphoMed raised?

OrphoMed has raised $41.8M in total funding, most recently a series a round.

Where is OrphoMed headquartered?

OrphoMed is headquartered in Bay Area, California, United States.

OrphoMed

Q: Who are OrphoMed's investors?

OrphoMed's investors include New Enterprise Associates, Takeda (JP), Pappas Capital, Relativity Healthcare Partners.

Bay Area, United States · Founded 2015 · $41.8M raised

Biotech

Headquarters: Bay Area, California
Employees: 1–10
Founded: 2015
Business Model: B2B

Total Funding: $41.8M
Last Round: $39.0M Series AMay 2017
Rounds: 2

About

OrphoMed is a clinical-stage biopharmaceutical company based in San Francisco, California focused on developing novel first-in-class dimer therapeutics. The company's pipeline targets gastrointestinal conditions including irritable bowel syndrome with diarrhea and opioid bowel dysfunction. OrphoMed received FDA Fast Track designation for its lead compound ORP-101 and reported positive Phase 2 results in 2022.

Summary

OrphoMed is a Biotech company based in Bay Area, United States, founded in 2015. It has raised $41.8M in total across 2 rounds, most recently a $39.0M Series A round in May 2017. Investors include New Enterprise Associates, Takeda (JP) and Pappas Capital.